治疗双相抑郁的新型抗精神病药物鲁拉西酮

Lurasidone: a new antipsychotic for treatment of bipolar depression

双相抑郁是双相情感障碍的临床亚型之一,其病程复杂多变,不易识别且治疗困难。鲁拉西酮是一种新型非典型抗精神病药,为多巴胺D2、5-HT2A及5-HT7受体拮抗剂,于2010年被美国食品和药物管理局(FDA)批准用于治疗成人精神分裂症。2013年FDA批准鲁拉西酮新的适应证,可用于成人双相Ⅰ型情感障碍抑郁发作。本文主要对鲁拉西酮在双相抑郁的临床应用及研究进展作一综述,并对该药在精神分裂症中的临床应用及其药理作用机制、药动学、安全性、用法用量等作相应概述。

Bipolar depression is one of the clinical subtypes of bipolar disorder, which is difficult to identify and treat. Lurasidone, a new type of atypical antipsyehotie and dopamine D2, 5-HTzA and 5-HT7 receptor antagonist, was approved for treatment of adult schizophrenia by FDA in 2010. Moreover, lurasidone was approved by FDA in 2013 for a new indication--bipolar I depression in adult patients. This paper mainly described the clinical application and studies of lurasidone in bipolar depression, and summarized the clinical application in schizophrenia and the action mechanism, pharmacokinetics, safety, usage and dosage of lurasidone.